Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -28,060 | -14,987 | -8,738 | -3,475 | -15,528 |
| Depreciation Amortization | 170 | 118 | 57 | 28 | 8 |
| Accounts payable and accrued liabilities | 438 | 2,001 | 641 | 202 | N/A |
| Other Working Capital | 1,163 | 4,962 | 839 | 88 | 902 |
| Other Operating Activity | -420 | -4,060 | -1,972 | -1,040 | -632 |
| Operating Cash Flow | $-26,709 | $-11,966 | $-9,173 | $-4,197 | $-15,250 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -31 | -16 | -6 | N/A | -4 |
| Investing Cash Flow | $-31 | $-16 | $-6 | $N/A | $-4 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 86,977 | 23 | 23 | 23 | N/A |
| Other Financing Activity | 5,598 | 1,354 | 4,974 | 5,410 | 56,367 |
| Financing Cash Flow | $92,576 | $1,377 | $4,997 | $5,433 | $56,367 |
| Exchange Rate Effect | -1,423 | -2,737 | -499 | -1,229 | 162 |
| Beginning Cash Position | 65,676 | 65,676 | 65,676 | 65,676 | 24,401 |
| End Cash Position | 130,089 | 52,334 | 60,995 | 65,683 | 65,676 |
| Net Cash Flow | $64,413 | $-13,342 | $-4,681 | $7 | $41,274 |
| Free Cash Flow | |||||
| Operating Cash Flow | -26,709 | -11,966 | -9,173 | -4,197 | -15,250 |
| Capital Expenditure | -31 | -16 | -6 | N/A | N/A |
| Free Cash Flow | -26,740 | -11,983 | -9,179 | -4,197 | -15,250 |